Takeda snaps up LigoCyte for $60M

Takeda acquired LigoCyte Pharmaceuticals for $60 million, with potential future payouts that were undisclosed. The Japanese company snapped up LigoCyte's lead vaccine candidate against a notorious foodborne stomach bug called norovirus gastroenteritis. The buyout follows the launch of Takeda's new vaccine division in January. Story

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.